Human ASPL/TUG interacts with p97 and complements the proteasome mislocalization of a yeast <i>ubx4</i> mutant, but not the ER-associated degradation defect by Madsen, Louise et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Human ASPL/TUG interacts with p97 and complements the proteasome mislocalization
of a yeast ubx4 mutant, but not the ER-associated degradation defect
Madsen, Louise; Hansen, Karen Molbæk; Larsen, Ida B.; Nielsen, Sofie V.; Poulsen, Esben
Guldahl; Walmod, Peter Schledermann; Hofmann, Kay; Seeger, Michael; Chien, Chen-Ying;
Chen, Rey-Huei; Kriegenburg, Franziska; Hartmann-Petersen, Rasmus
Published in:
B M C Cell Biology
DOI:
10.1186/1471-2121-15-31
Publication date:
2014
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Madsen, L., Hansen, K. M., Larsen, I. B., Nielsen, S. V., Poulsen, E. G., Walmod, P. S., ... Hartmann-Petersen,
R. (2014). Human ASPL/TUG interacts with p97 and complements the proteasome mislocalization of a yeast
ubx4 mutant, but not the ER-associated degradation defect. B M C Cell Biology, 15, [15:31].
https://doi.org/10.1186/1471-2121-15-31
Download date: 03. Feb. 2020
Madsen et al. BMC Cell Biology 2014, 15:31
http://www.biomedcentral.com/1471-2121/15/31RESEARCH ARTICLE Open AccessHuman ASPL/TUG interacts with p97 and
complements the proteasome mislocalization of a
yeast ubx4 mutant, but not the ER-associated
degradation defect
Louise Madsen1†, Karen Molbæk1†, Ida B Larsen1, Sofie V Nielsen1, Esben G Poulsen1, Peter S Walmod2,
Kay Hofmann3, Michael Seeger4, Chen-Ying Chien5, Rey-Huei Chen5, Franziska Kriegenburg1* and
Rasmus Hartmann-Petersen1*Abstract
Background: In mammalian cells, ASPL is involved in insulin-stimulated redistribution of the glucose transporter
GLUT4 and assembly of the Golgi apparatus. Its putative yeast orthologue, Ubx4, is important for proteasome
localization, endoplasmic reticulum-associated protein degradation (ERAD), and UV-induced degradation of RNA
polymerase.
Results: Here, we show that ASPL is a cofactor of the hexameric ATPase complex, known as p97 or VCP in
mammals and Cdc48 in yeast. In addition, ASPL interacts in vitro with NSF, another hexameric ATPase complex.
ASPL localizes to the ER membrane. The central area in ASPL, containing both a SHP box and a UBX domain, is
required for binding to the p97 N-domain. Knock-down of ASPL does not impair degradation of misfolded secretory
proteins via the ERAD pathway. Deletion of UBX4 in yeast causes cycloheximide sensitivity, while ubx4 cdc48-3
double mutations cause proteasome mislocalization. ASPL alleviates these defects, but not the impaired ERAD.
Conclusions: In conclusion, ASPL and Ubx4 are homologous proteins with only partially overlapping functions.
Both interact with p97/Cdc48, but while Ubx4 is important for ERAD, ASPL appears not to share this function.
Keywords: Ubiquitin, Proteasome, Chaperone, DegradationBackground
The protein, named alveolar soft part sarcoma locus
(ASPL), was first described as part of an oncogenic fusion
protein with a transcription factor in alveolar soft part sar-
coma tumors [1]. The normal, unfused ASPL protein con-
tains an N-terminal UBL domain and a C-terminal UBX
domain and orthologues are present in most eukaryotic
species. However, the function of the ASPL protein
remained unknown until it appeared in a functional
screen for proteins involved in insulin-stimulated re-
distribution of the glucose transporter GLUT4 [2]. It* Correspondence: fkriegenburg@bio.ku.dk; rhpetersen@bio.ku.dk
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unless otherwise stated.was shown that ASPL binds GLUT4 directly and se-
questers GLUT4 to intracellular vesicles in the absence
of insulin, and ASPL was thus also named TUG for
“tether containing UBX domain for GLUT4” [2]. Fur-
ther studies revealed that depletion of ASPL/TUG by
siRNA also enhances GLUT4 translocation to the
plasma membrane and glucose uptake in adipocytes
[3]. More recently, ASPL/TUG was shown to regulate
assembly of the Golgi compartment [4].
Previous studies have linked both integral UBL domain
proteins [5] and UBX domain proteins [6] to the ubiquitin-
proteasome system, and since ASPL contains both, it is
likely also to play a role in intracellular proteolysis. The
structure of the ASPL/TUG UBL domain has been solved
[7]. The structure shows the typical ubiquitin-like β-grasp
fold, although some differences to ubiquitin, in particularl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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noted. Some UBL domain-containing proteins, such as hu-
man BAG-1 [8] and yeast Rad23 [9], utilize their UBL do-
mains to interact with subunits of the 26S proteasome.
However, the UBL domain is not a general proteasome-
interacting domain [10] and binding to unrelated compo-
nents has been reported [11]. In the case of ASPL, the
UBL domain was recently proposed to become cleaved
and function as a novel ubiquitin-like modifier [12].
The UBX domains also resemble ubiquitin and ubiquitin-
like domains [13], and with few exceptions, all characterized
UBX domains are implicated in binding to the AAA
(ATPase associated with various activities) ATPase, known
as p97 or valosin-containing protein (VCP) in mammals
and Cdc48 in yeast [6,14,15]. Structurally, p97 resembles an-
other AAA type ATPase specifically involved in vesicle fu-
sion, named NSF [16]. The p97 ATPase is a ring-shaped
homohexameric chaperone-like complex [17-21]. The
monomer is a phylogenetically highly conserved protein
that contains two AAA modules, called D1 and D2, that
couple coordinated ATP-hydrolysis to conformational
changes of the hexameric complex [22]. The ATP-driven
conformational changes allow p97 to physically disassem-
ble protein complexes and segregate proteins from their
binding partners [23,24]. This “segregase” activity [25,19] is
probably limited to ubiquitylated proteins and is essential
for a number of cellular pathways, including membrane
fusion [26], protein degradation [27,28] and transcription
factor maturation through limited degradation [29,25].
Although p97 may bind ubiquitylated substrates directly
[25], a series of p97 cofactors that recruit and/or process
substrates has been characterized [30]. Functionally, these
cofactors are diverse, and each probably directs p97 to a
particular cell function. For instance, the UBX domain pro-
teins p47 and Ubxd7 direct p97 to functions in membrane
fusion [26] and protein degradation [15,31], respectively.
Previous studies have also connected p97 and its
cofactors with the degradation of misfolded proteins,
derived from endoplasmic reticulum (ER), via the ER-
associated degradation (ERAD) pathway [32,33]. In this
degradation pathway, misfolded secretory proteins are
first recognized by ER luminal chaperones. Then, the
proteins are retrotranslocated back to the cytoplasm,
ubiquitylated, and finally degraded by the 26S prote-
asome [34]. The energy used to extract the proteins is
provided by p97-catalyzed ATP-hydrolysis.
The putative yeast orthologue of the human UBX-
domain protein ASPL, Ubx4, has been shown to regulate
ERAD [35], and UV-induced degradation of RNA poly-
merase [36]. More recently, it was shown that budding
yeast cdc48 and ubx4 double mutants mislocalize 26S
proteasomes into foci at the nuclear envelope [37].
Moreover, ubx4 null mutants display synthetic lethality
with deletion mutants in the rpn4 transcriptionalactivator for proteasome subunits and ump1, encoding
a proteasome-assembly chaperone [37], suggesting that
Ubx4 regulates proteasome maturation and trafficking.
For our understanding of p97, it is important that we
obtain more detailed knowledge of its various cofactors,
of which at least 20 have been found so far [30]. Using a
yeast two-hybrid approach, we identified ASPL as a p97
cofactor. Our characterization of ASPL revealed that
ASPL is a widely expressed protein that binds directly to
p97 and NSF. Although human ASPL only displays weak
sequence similarity to its putative yeast orthologue,
Ubx4, expression of human ASPL in a budding yeast
ubx4Δ mutant partially rescues the cycloheximide sensi-
tivity and proteasome mislocalization phenotypes in
ubx4Δ strains. This suggests that ASPL is a functional
orthologue of yeast Ubx4. However, the ERAD defect in
the ubx4 null mutant is not affected by ASPL expression,
and knock-down of ASPL expression in human cells
does not lead to a stabilization of the model ERAD sub-
strates, CD3δ and TCRα. Collectively, this suggests that
human ASPL and budding yeast Ubx4 are multifunc-
tional proteins that share some, but not all functions.
Results and discussion
ASPL is a conserved eukaryotic protein that interacts with
p97
In a yeast two-hybrid screen of a HeLa cell cDNA li-
brary, using human p97 as a bait, several UBX domain
proteins were found. These included p47, ASPL as well
as Ubxd1, Ubxd2, Ubxd8, and Rep8 (Figure 1a). Previ-
ously, most of these proteins have been described in the
context of p97-binding, and connected with p97-relevant
functions [26,15,38,39]. The human ASPL protein is 77%
identical with its murine orthologue and 47% identical
with its orthologue in Xenopus laevis (Additional file 1:
Figure S1). ASPL is found in most eukaryotes. The closest
homologue to ASPL in plants is PUX1, a known p97
cofactor [40,41]. The putative budding yeast ortholo-
gue is Ubx4. However, Ubx4 is only weakly homolo-
gous to human ASPL (18% overall sequence identity)
(Additional file 1: Figure S2). ASPL contains a UBL do-
main near the N-terminus, and a UBX domain near the
C-terminus (Additional file 1: Figure S1). In addition, by
sequence analyses we found a low homology UBX domain
at position 89–169 which we named LHU for low hom-
ology UBX domain and a putative p97-binding SHP-box
between residues 244 and 254. Curiously, the SHP box is
not conserved in budding yeast Ubx4 (Additional file 1:
Figure S2). The UBX domain and SHP box are regarded
as general p97-interacting modules, indicating that ASPL
was a valid target of p97 in the yeast two-hybrid screen.
To obtain further information on ASPL interacting
proteins, we performed another round of yeast two-
hybrid screening, now using full length ASPL as bait.
Figure 1 ASPL interacts with p97 via the UBX domain. (a) Yeast two-hybrid analyses of p97 using the HIS3 reporter gene. Co-transformation
of p97 bait with the indicated p97 binding partner preys supported cell growth under conditions selecting for interaction (in the absence of
histidine and the presence of 25 mM 3-aminotriazol (3AT)) (right panel). An empty prey vector served as a negative control. (b) Yeast two-hybrid
analyses of ASPL using the HIS3 reporter gene. Co-transformation of ASPL bait with p97 or NSF preys supported cell growth under conditions selecting
for interaction (in the absence of histidine and the presence of 25 mM 3-aminotriazol (3AT)) (right panel). An empty prey vector served as a negative
control. (c) Purified 6His-tagged p97 was incubated with GST or GST-tagged ASPL and precipitated with glutathione (GSH) Sepharose. Bound proteins
were analyzed by SDS-PAGE and blotting using antibodies to p97 (upper panel) Even loading was checked by staining with Coomassie Brilliant Blue
(CBB) (lower panel). (d) Purified 6His-tagged NSF was incubated with GST or GST-tagged ASPL and precipitated with glutathione (GSH) Sepharose.
Bound proteins were analyzed by SDS-PAGE and blotting using antibodies to the 6His-tag on NSF (upper panels). Even loading was checked by
staining with Coomassie Brilliant Blue (CBB) (lower panel). Interaction to NSF was only evident when no detergents were included in the
buffer system. In the presence of 0.5% Triton X-100 no interaction between ASPL and NSF was observed. (e) MelJuSo cell lysates were used
in immunoprecipitation (IP) experiments with antibodies to ASPL and Protein A Sepharose or as a control Protein A Sepharose beads only.
SDS-PAGE and blotting revealed that ASPL co-precipitated p97, but not NSF or the Rpn1 or α subunits of the 26S proteasome.
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ethylmaleimide (NEM) sensitive factor (NSF). When
comparing the p97 and NSF clones, we noticed that p97
activated the HIS3 reporter gene stronger than did NSF
(Figure 1b).
In order to confirm the yeast two-hybrid interactions,
GST and GST-tagged ASPL (Figure 1c and Figure 1d) were
expressed and purified from E. coli. The fusion proteins
were used in precipitation experiments with 6His-tagged
p97 and 6His-tagged NSF, produced in E. coli. GST-ASPL
precipitated p97 (Figure 1c) and NSF (Figure 1d) whereas,
under the same conditions, GST did not, thus confirming
that ASPL interacts directly with p97 and NSF. However,
we noted that the ASPL-NSF interaction was lost when de-
tergents were included in the buffer system (Figure 1d).
To determine if the identified protein-protein interac-
tions also occur in vivo, between the endogenous pro-
teins, we immunoprecipitated ASPL from mammalian
cell extracts and analyzed the precipitated material byblotting for p97 and NSF. Indeed, the interaction between
p97 and ASPL was also evident between the endogenous
proteins (Figure 1e). However, we did not detect any NSF
in the immunoprecipitates (Figure 1e), even after chemical
cross-linking (not shown). This suggests that either the
ASPL-NSF interaction in vivo is weak and/or transient, or
that the proteins do not interact in vivo. We therefore de-
cided not pursue the interaction between NSF and ASPL
further. Since ASPL contains a UBL domain, and some
UBL domain proteins function as proteasome co-factors
[10], we also tested if ASPL interacts with 26S protea-
somes. However, since neither the Rpn1 subunit of the
19S proteasome complex nor the α-subunits 20S prote-
asome complex were recovered in the ASPL immunopre-
cipitate, we conclude that APSL is not associated with 26S
proteasomes in mammalian cells (Figure 1e).
Next, we decided to map the interaction between
ASPL and p97. Further GST-precipitation experiments
using full length ASPL and various ASPL truncations
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was not able to precipitate p97 (Figure 2b). Curiously,
the construct, lacking the UBX domain, did also not co-
precipitate p97 (Figure 2b), indicating that efficient bind-
ing to ASPL requires an extended central area containing
multiple interaction areas. Further truncations revealed
that the N-terminal half of ASPL, containing the UBL and
LHU domains, failed to interact with p97 (Figure 2b),
while the central area containing the SHP box and UBX
domain did bind p97 (Figure 2b), although with a reduced
affinity. Further co-precipitation experiments using trun-
cated 6His-tagged versions p97 (Figure 2c) and full length
GST-tagged ASPL revealed that ASPL interacts with the
p97 N-domain (Figure 2d). We conclude that ASPL asso-
ciates with the p97 N-domain via the central area, con-
taining the SHP box and UBX domain.
ASPL is a widely expressed protein and localizes to the
ER-membrane
Since p97 and NSF are connected with a range of basic
cellular functions, their cofactors are expected to beFigure 2 ASPL interacts with the p97 N-domain. (a) Schematic diagram
the precipitation experiments. (b) Purified 6His-tagged p97 was incubated
with glutathione (GSH) Sepharose. Bound proteins were analyzed by SDS-PAG
Even loading was checked by staining with Coomassie Brilliant Blue (CBB) (low
the various truncations used in the precipitation experiments. (d) Purified 6H
GST-tagged ASPL before precipitation and analysis by SDS-PAGE and blo
(upper panel). Even loading was checked by staining with Coomassie Brwidely expressed. However, some p97 cofactors display
a very narrow tissue expression profile [39]. To deter-
mine the tissue distribution of ASPL on the protein
level, we separated protein extracts from various rat
tissues by SDS-PAGE and probed blots for the pres-
ence of ASPL. We found that ASPL was expressed in
all the tested tissues, but was less abundant in kidney
(Figure 3a).
Next, we sought to determine the subcellular localization
of ASPL. Separation of cell lysates into a soluble and
insoluble fraction revealed that ASPL is largely soluble
(Figure 3b).
Recently, endogenous ASPL was shown to co-localize
with ERGIC-53 at the ER-Golgi intermediate compart-
ment [4]. In our hands, the commercially available anti-
bodies to ASPL were not functional for immunofluorescence
microscopy. HeLa cells were therefore transiently transfected
to express full length ASPL with a C-terminal GFP-tag. The
GFP signal appeared throughout the cells, but was increased
at the ER, as determined by concurrent staining of the ER
protein, calnexin (Figure 3c).of the ASPL domain organization and the various truncations used in
with GST or the indicated GST-tagged ASPL truncations and precipitated
E and blotting using antibodies to the 6His-tag on p97 (upper panel).
er panel). (c) Schematic diagram of the p97 domain organization and
is-tagged p97 and p97 truncations were incubated with GST and
tting using antibodies specific for the 6His-tagged p97 proteins
illiant Blue (CBB) (lower panel).
Figure 3 Expression and localization of ASPL. (a) The rat tissues were analyzed by SDS-PAGE and blotting using antibodies specific for ASPL
(upper panel) and tubulin (lower panel). ASPL was present in most tissues, but less abundant in kidney. (b) HeLa cells lysates were separated by
centrifugation into a soluble (Sol.) and insoluble (Pellet) fraction and analyzed by SDS-PAGE and blotting using antibodies to the listed proteins.
Calnexin served as a control for an insoluble (transmembrane) protein, while Txnl1 served as a control for a soluble protein. (c) Confocal micrographs
of HeLa cells transfected to express ASPL with a C-terminal GFP-tag. The localization of ASPL in formaldehyde-fixed cells was detected with anti-GFP
antibodies (green) (left panel), and compared with the localization of the ER protein calnexin (red) (middle panel). In the merged image
(right panel), the signals overlap partially (yellow). The presented cells are derived from different confocal scans. Size-bar = 10 μm.
Figure 4 ASPL does not influence the degradation of model
ERAD substrates. (a) MelJuSo cells were transfected with control
siRNA or two different siRNAs, specific for ASPL. After 3 days, the
expression of the indicated proteins was analyzed by SDS-PAGE and
blotting. Actin served as a loading control. (b) MelJuSo cells expressing
YFP-tagged CD3δ were analyzed in cultures treated with cycloheximide.
At the indicated times the amount of CD3δ-YFP was analyzed by
SDS-PAGE and Western blotting using the indicated antibodies.
Antibodies to α-tubulin were used for the loading control. (c) HeLa
cells expressing HA-tagged TCRα were analyzed in cultures treated
with cycloheximide. At the indicated times the amount of TCRα-HA
was analyzed by SDS-PAGE and Western blotting using the indicated
antibodies. Antibodies to α-tubulin were used for the loading control.
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Since ASPL is a putative orthologue of yeast Ubx4,
which has been connected to ERAD [35], the ERAD
pathway might also be impaired in cells with a decreased
amount of ASPL. To test this prediction, ASPL expres-
sion was knocked-down with siRNA (Figure 4a), and the
degradation kinetics of the model ERAD substrates
CD3δ-YFP (Figure 4b) and TCRα-HA (Figure 4c) were
analyzed. We observed no significant differences in these
substrates degradation kinetics when ASPL was lacking
(Figure 4b and Figure 4c). We therefore conclude that
ASPL, unlike its putative yeast orthologue Ubx4, is not
involved in ERAD, at least with these substrates.
ASPL complements some defects of a budding yeast
ubx4Δ strain
Yeast mutants lacking Ubx4 have been reported to be
sensitive to stress conditions, including high tempera-
tures, reducing agents and cycloheximide [35]. To test
whether ASPL is a functional orthologue of yeast Ubx4,
we examined whether expression of human ASPL could
rescue the cycloheximide sensitive phenotype of the
UBX4 deletion mutant in S. cerevisiae. To this end, wild
type and ubx4Δ strains were transformed with an expres-
sion plasmid encoding ASPL and, as a control, an empty
vector. Under normal conditions, cell growth was not af-
fected by loss of Ubx4 or expression of ASPL (Figure 5a).
However, expression of ASPL (Figure 5b) partially rescued
the cycloheximide-dependent growth defect of the ubx4Δ
mutant (Figure 5a), revealing that ASPL, at least in part,
can remedy the lack of Ubx4 in ubx4Δ cells. To examine
Figure 5 Human ASPL partially suppresses some defects of a yeast ubx4Δ mutant. (a) Serial dilutions of wild type or ubx4Δ strains
transformed with either a control plasmid (Mock) or an ASPL expression vector (ASPL) were spotted onto solid media with or without 0.2 μg/mL
cycloheximide (CHX). The plates were incubated at 30°C until colonies formed. (b) Extracts from the indicated strains were resolved by SDS-PAGE
and blotting using antibodies to ASPL and, as a loading control, the constitutive Pma1. (c) Wild type (wt) and ubx4Δ cells expressing CPY* were
treated with cycloheximide. At the indicated times the amount of CPY* was analyzed by SDS-PAGE and Western blotting using the indicated
antibodies. (d) Wild-type yeast and cdc48-3 PGAL-3HA-UBX4 mutant expressing Pre6-GFP and nuclear envelope marker Nup49-mCherry were
grown in synthetic medium containing glucose and analyzed by fluorescence microscopy. (e) Yeast 2 μ plasmids carrying ASPL or UBX4
genes were transformed into PRE6-GFP cdc48-3 PGAL-3HA-UBX4 strain. Transformation with the empty vector pRS426 serves as negative control.
Cells were grown in synthetic medium containing galactose or glucose to induce or repress, respectively, UBX4 and analyzed by fluorescence
microscopy. (f) The percentage of cells containing Pre6-GFP foci were quantified and shown as average and standard deviation for
three independent experiments. Bar, 2 μm. (**, p < 0.01).
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in the ubx4Δ strain, we followed the degradation of the
ERAD substrate CPY*. As expected, we found that dele-
tion of UBX4 led to an impaired degradation of CPY*
(Figure 5c). However, ectopic expression of ASPL had no
effect on the CPY* degradation (Figure 5c).More recently, Ubx4 was shown to regulate prote-
asome localization along with Cdc48 [37]. In mamma-
lian cells, proteasomes are distributed throughout the
cytosol and nucleus [42], while in budding yeast, protea-
somes are enriched in the nucleus [43]. We found that
proteasomes, as visualized by Pre6-GFP, concentrated to
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through GAL promoter in the cdc48-3 strain (Figure 5d).
This mislocalization was fully suppressed by ectopic ex-
pression of UBX4, and partially suppressed by expression
of ASPL (Figure 5,e and f), revealing that this function is
conserved between the yeast and human proteins.
Finally, we tested if ASPL also affected proteasome
localization in human cells. Under normal conditions we
found proteasomes fairly evenly spread throughout the
cytosol and nucleus (Additional file 1: Figure S3), and this
localization was not changed upon knock-down of ASPL
expression (Additional file 1: Figure S3). Hence, either
ASPL does not regulate the subcellular localization of pro-
teasomes in mammalian cells, or perhaps this function of
ASPL is redundant with other components in higher
eukaryotes.
Conclusions
Recently, it was reported that ASPL is required for re-
assembly of the Golgi apparatus [4]. On most points,
e.g. association with p97, interaction mapping and
subcellular localization, our data largely agree with
these published results. In addition, we show here that
human ASPL can partially complement the cyclohexi-
mide sensitive phenotype and proteasome mislocaliza-
tion of budding yeast mutants, devoid of Ubx4. However,
heterologous ASPL expression does not restore ERAD in
the ubx4Δ mutant. Thus, unlike Ubx4, human ASPL is
not involved in ERAD, but rather shares some other cellu-
lar functions with Ubx4, including regulation of prote-
asome localization.
Methods
Buffers
The buffers were: Buffer A, 25 mM Tris/HCl pH 7.5,
2 mM MgCl2, 2 mM ATP, 50 mM NaCl, 1 mM DTT,
10% (v/v) glycerol, 0.1% (v/v) Triton X-100. Buffer B,
33 mM Hepes pH 7.3, 150 mM potassium acetate, 10%
(v/v) glycerol, 1% (w/v) DeoxyBigChap (Fluka). Buffer C,
33 mM Hepes pH 7.3, 150 mM potassium acetate, 10%
(v/v) glycerol, 0.2% (w/v) DeoxyBigChap (Fluka), 1 mg/
mL BSA. Buffer D, 25 mM Tris/HCl pH 7.5, 2 mM ATP,
50 mM NaCl, 1 mM DTT, 10% (v/v) glycerol. In cell ly-
sates, all buffers were supplemented with Complete pro-
tease inhibitor cocktail tablets (EDTA-free, Roche) and
1 mM PMSF.
Plasmids and expression
For expression of recombinant ASPL, full-length cDNA
and various truncations encoding human ASPL were
transferred to the appropriate Gateway destination vec-
tors (Invitrogen). The expression constructs for human
p97 were kindly provided by Prof. Hemmo H. Meyer
(Zürich, Switzerland). The expression construct for 6His-tagged NSF was kindly provided by Prof. Sidney W.
Whiteheart (Kentucky, USA). Transformed E. coli BL21*
(DE3), M15 or Rosetta cells, expressing tagged protein,
were lysed by sonication in one volume of buffer A for
p97-related experiments and in buffer D for NSF-related
experiments. The extracts were cleared by centrifugation
(12000 g, 30 min) and the fusion protein was purified by
standard methods.
Yeast two-hybrid
Yeast two-hybrid screening using full length human p97
was performed on a HeLa cell cDNA library (Invitrogen)
using the ProQuest yeast two-hybrid system (Invitrogen)
according to the protocol supplied by the manufacturer.
Saccharomyces cerevisiae strains and techniques
The genetic backgrounds of the S. cerevisiae strains used
in this study were W303 (MATα ade2-locre can1-100
his3-11, 15 leu2-3, 112 trp1-1 ura3-1 prc1-1) and W303
ubx4::kanMX [35]. These strains were generously pro-
vided by Prof. Dieter H. Wolf (Stuttgart, Germany). The
strains were transformed using lithium acetate with ex-
pression plasmids for human ASPL or as a control
pEMBLyex4.
Cell culture
MelJuSo cells, stably transfected to express YFP-tagged
CD3δ [44], were kindly supplied by Dr. Nico P. Dantuma
(Stockholm, Sweden). HeLa cells, stably transfected to ex-
press HA-tagged TCRα [45], were kindly provided by
Dr. Cezary Wojcik (Evansville, USA). These cells and
standard HeLa cells were maintained in Dulbecco’s modi-
fied Eagle’s minimal essential medium (DMEM) supple-
mented with 10% newborn-calf serum (Invitrogen) at 37°C
in a humidified atmosphere containing 7.5% CO2.
Electrophoresis and blotting
Proteins were separated on 7 cm x 8 cm 12.5% acrylamide
gels. Proteins were transferred to BA83 (Schleicher &
Schuell) nitrocellulose membranes and probed with anti-
bodies as indicated.
Antibodies
Antibodies and their sources were: anti-human ASPL
(Abcam and Cell Signaling), anti-NSF (NSF-1 monoclonal
purchased from Abcam), anti-his (Qiagen), anti-GFP (Invi-
trogen), anti-tubulin and anti-β-actin (Abcam), anti-human
Rpn1 (p112, Enzo) and anti-20S proteasome α-subunits
(MCP231, Enzo). The antibodies to p97 have been described
previously [46]. Several antibodies were kindly provided by
the following investigators: anti-calnexin (Prof. Ari Helenius,
Zürich, Switzerland), anti-Pma1 (Prof. Per A. Pedersen,
Copenhagen, Denmark), anti-CPY* (Prof. Jakob R. Winther,
Copenhagen, Denmark).
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The transformed yeast strains were grown to late expo-
nential phase and lysed directly or used for cyclohexi-
mide decay assays prior lysis. Cell lysis was performed
using NaOH. Briefly, cells were harvested and resus-
pended in 1–2 volumes water. A 0.6 M NaOH stock so-
lution was added to give a final concentration of 0.1 M
NaOH and the cells were incubated for 5 min at room
temperature. Subsequently, the cells were pelleted and
resuspended in SDS sample buffer, boiled for 20 minutes
and finally sonicated for 20 seconds.
For growth assays, cells in exponential phase were
washed once in water and resuspended to an OD600nm
of 0.4 in water. Five-fold dilution series were prepared of
each culture in water and 5 μL of each dilution were
spotted onto solid minimal media with or without
0.2 μg/mL cycloheximide and grown at 30°C.
Transfection of siRNA
HeLa cells expressing HA-tagged TCRα or MelJuSo cells
expressing YFP-tagged CD3δ were forward transfected
with 50 nM siRNA using either DharmaFECT (Dharma-
con) or Lipofectamine RNAiMAX (Invitrogen), respect-
ively. Briefly for HeLa, exponentially growing cells were
washed in PBS and incubated for 24 hours with a solu-
tion containing siRNA, 0.4% Dharmafect in DMEM sup-
plemented with 1% calf serum. The medium was then
changed to DMEM with 10% serum. For MelJuSo cells,
the siRNA and Lipofectamine RNAiMAX were mixed
directly in OptiMEM (Invitrogen) and carefully added to
exponentially growing cell. Cycloheximide decay assays
were performed 72 hours after transfection.
Co-precipitation experiments
For in vitro binding studies, GST and GST-tagged ASPL
variants were expressed in E. coli and bound to Glutathi-
one Sepharose (GE Healthcare). Equal amounts of puri-
fied, immobilized proteins were incubated with cleared
E. coli lysate containing either recombinant 6His-tagged
p97 or 6His-tagged NSF for 2 hours at 4°C under gentle
agitation. Subsequently, the lysate was removed and the
beads were washed 3 times in buffer A for p97 and in
buffer D for NSF pull downs. The immobilized proteins
were eluted in 4 x SDS sample buffer, subjected to SDS-
PAGE and visualized by Western blotting and/or Coo-
massie Brilliant Blue staining.
For in vivo binding studies, HeLa cells were lysed in
buffer B under gentle agitation for 30 min for p97-
related experiments. For NSF-related experiments Mel-
JuSo cells were resuspended in buffer D and lysed via
sonication. Cell extracts were cleared by centrifugation
at 12000 g for 20 minutes and either incubated with
Protein A Sepharose alone as a control or with an anti-
body to ASPL (1:100, Cell Signaling) for 30 minutes at4°C before adding Protein A Sepharose (GE Healthcare)
to the antibody containing samples. After further incu-
bation for 1.5 hours at 4°C under gentle agitation, the
supernatant was carefully removed and the beads were
washed 3 times in either buffer C or in buffer D for p97
or NSF co-precipitation, respectively. Bound proteins
were eluted in SDS sample buffer, subjected to SDS-
PAGE and visualized by Western blotting.
Protein degradation experiments
The degradation of CD3δ-YFP, TCRα-HA and CPY* was
followed in cultures treated with cycloheximide as de-
scribed [47,35].
Differential centrifugation
Differential centrifugation was performed as described [48].
Fluorescence microscopy of HeLa cells
For fluorescence microscopy, HeLa cells were plated in
4-well Permanox LabTek chamber slides (Nunc) and
transiently transfected with plasmids for expression of
ASPL and ASPL truncations with a C-terminal GFP-tag,
using Lipofectamine 2000 according to the manufac-
turer’s instructions (Invitrogen). About 48 hours after
transfection, cells were fixed in formaldehyde and stained
with mouse anti-GFP and rabbit anti-calnexin in combin-
ation with Alexa 488-conjugated goat anti-mouse and
Alexa 543-conjugated goat anti-rabbit antibodies (Invitro-
gen), respectively.
Confocal micrographs were obtained with a Radiance
2000 confocal laser scanning system (BioRad) attached
to an inverted Nikon Eclipse TE 200 microscope. Scans
were performed with a pixel resolution of 0.062 μm
using a 60x objective, Ar and HeNe lasers, a 560 DCLP
dichroic mirror, a HQ 515/30 emission filter (for Alexa
488) and an E570LP emission filter (for Alexa 543).
For the immunofluorescence microscopy of protea-
somes in HeLa cells, siRNAs were transfected using
RNAiMAX (Invitrogen) 48 hours prior to fixation in for-
malin (Sigma). The cells were then washed in PBS and
permabelized in 0.2% Triton X-100 in PBS for 5 minutes
at room temperature before 5 mg/mL BSA (Sigma) in
20 mM glycine in PBS was applied for 30 minutes at room
temperature. The antibodies used for detection were:
MCP34 to proteasome subunit α4 (Enzo) and TBP1-19 to
proteasome subunit Rpt5 (Enzo) diluted 1:100, and Alexa
Fluor 594 goat anti-mouse IgG (Invitrogen) diluted 1:1000.
Images were acquired using a fluorescence microscope
(Zeiss AxioImager Z1) and CCD camera (Hamamatsu
ORCA-ER).
Fluorescence microscopy of yeast cells
For experiments on proteasome localization, cells were
first grown in synthetic medium lacking uracil to maintain
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UBX4. At early exponential phase, the cell culture was ei-
ther maintained in the same medium or shifted to glucose
medium to suppress UBX4 for another 3 hours at 25°C.
The fluorescence images were acquired with a 100x
1.4 N/A objective and CoolSNAP HQ2 CCD camera
(Photometircs) on Olympus IX71 fluorescence microscope
controlled by DeltaVision system (Applied Precision).
Z-stacks of 13 optical sections with 0.5 μm spacing
were collected and processed by Softworx software.
Projections of maximum intensity were shown.
Supporting data
The present article contains supporting data.
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Additional file 1: Supplementary figures and legends.
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